Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity

Featured Article:

Ricardo V. Cohen, M.D., Jose C. Pinheiro, M.D., Carlos A. Schiavon, M.D., João E. Salles, M.D., Bernardo L. Wajchenberg, M.D., David E. Cummings,

M.D.

Diabetes Care Volume 35: 1420-1428

July, 2012

Study Objectives

 

Cohen R et al. Diabetes Care 2012;35:1420-1428

• Roux-en-Y gastric bypass (RYGB) ameliorates type 2 diabetes in severely obese patients through mechanisms beyond just weight loss, and it may benefit less obese diabetic patients

• Study determined the long-term impact of RYGB on patients with diabetes and only class I obesity (BMI 30–35 kg/m2 )

Study Design & Methods

• Sixty-six consecutively selected diabetic patients with BMI 30–35 kg/m2 underwent RYGB in a tertiary-care hospital and were prospectively studied for up to 6 years (median 5 years [range 1–6]), with 100% follow-up

• Main outcome measures were safety and the percentage of patients experiencing diabetes remission (HbA1c < 6.5% without diabetes medication)

Cohen R et al. Diabetes Care 2012;35:1420-1428

Cohen R et al. Diabetes Care 2012;35:1420-1428

Cohen R et al. Diabetes Care 2012;35:1420-1428

Cohen R et al. Diabetes Care 2012;35:1420-1428

Cohen R et al. Diabetes Care 2012;35:1420-1428

Cohen R et al. Diabetes Care 2012;35:1420-1428

Conclusions

• Largest, longest-term study to date examining RYGB for diabetic patients without severe obesity

• RYGB safely and effectively ameliorated diabetes and associated comorbidities, reducing cardiovascular risk, in patients with a BMI of only 30–35 kg/m2

Cohen R et al. Diabetes Care 2012;35:1420-1428